Patents Assigned to Tolero Pharmaceuticals, Inc.
  • Patent number: 10568887
    Abstract: Combination therapies for treatment of cancer are provided. The disclosed methods comprise administration of a cyclin-dependent kinase inhibitor and a DNA methyltransferase inhibitor to a mammal in need thereof.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: February 25, 2020
    Assignee: Tolero Pharmaceuticals, Inc.
    Inventors: David J. Bearss, Steven L. Warner, Adam Siddiqui-Jain, Clifford J. Whatcott, Wontak Kim
  • Patent number: 10562925
    Abstract: Compounds having the following structure (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein one of R1, R2 or R3 is —P(?O)(OH)2, and the other two of R1, R2 and R3 are each H, are provided. Pharmaceutical compositions comprising the compounds, and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: February 18, 2020
    Assignee: TOLERO PHARMACEUTICALS, INC.
    Inventors: Adam Siddiqui-Jain, David J. Bearss
  • Patent number: 10472328
    Abstract: Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: November 12, 2019
    Assignee: TOLERO PHARMACEUTICALS, INC.
    Inventors: Koc-Kan Ho, Yong Xu, Michael David Saunders, Xiaohui Liu, Scott Albert Pearce, Kevin Bret Wright, Jason Marc Foulks, Kenneth Mark Parnell, Steven Brian Kanner, David Lee Vollmer, Jihua Liu
  • Patent number: 10422788
    Abstract: The present disclosure is generally directed to profiling peptides, compositions, and kits, as well as methods of use thereof. The profiling peptides comprise an Mcl-1 binding domain, and optionally a cellular uptake moiety. The methods of using such profiling peptides include predicting sensitivity of a cancer, selecting a treatment, treating a cancer, producing a sensitivity profile, and the like.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: September 24, 2019
    Assignee: TOLERO PHARMACEUTICALS, INC.
    Inventors: David J. Bearss, Adam Siddiqui-Jain, Clifford J. Whatcott, Peter W. Peterson, Steven L. Warner, Lars Mouritsen
  • Publication number: 20190282557
    Abstract: The present disclosure provides diagnostic methods useful for predicting a patient's response to alvocidib and guiding a physician decision to administer alvocidib to the patient.
    Type: Application
    Filed: May 29, 2019
    Publication date: September 19, 2019
    Applicant: Tolero Pharmaceuticals, Inc.
    Inventors: Steven L. Warner, David J. Bearss
  • Patent number: 10392392
    Abstract: The present invention provides substituted imidazo[1,2-b]pyridazines that are useful as protein kinase inhibitors and have one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. For example, a compound having the following structure: Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: August 27, 2019
    Assignee: Tolero Pharmaceuticals, Inc.
    Inventors: Yong Xu, Benjamin Gary Brenning, Steven G. Kultgen, Xiaohui Liu, Michael David Saunders, Koc-Kan Ho
  • Patent number: 10357488
    Abstract: The present disclosure provides diagnostic methods useful for predicting a patient's response to alvocidib and guiding a physician decision to administer alvocidib to the patient.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: July 23, 2019
    Assignee: Tolero Pharmaceuticals, Inc.
    Inventors: Steven L. Warner, David J. Bearss
  • Patent number: 10267787
    Abstract: The present disclosure is generally directed to profiling peptides, compositions, and kits, as well as methods of use thereof. The profiling peptides comprise an Mcl-1 binding domain, and optionally a cellular uptake moiety. The methods of using such profiling peptides include predicting sensitivity of a cancer, selecting a treatment, treating a cancer, producing a sensitivity profile, and the like.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: April 23, 2019
    Assignee: Tolero Pharmaceuticals, Inc.
    Inventors: David J. Bearss, Adam Siddiqui-Jain, Clifford J. Whatcott, Peter W. Peterson, Steven L. Warner, Lars Mouritsen
  • Patent number: 10259835
    Abstract: Compounds having the following structure (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein one of R1, R2 or R3 is —P(?O)(OH)2, and the other two of R1, R2 and R3 are each H, are provided. Pharmaceutical compositions comprising the compounds, and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: April 16, 2019
    Assignee: Tolero Pharmaceuticals, Inc.
    Inventors: Adam Siddiqui-Jain, David J. Bearss
  • Patent number: 10207996
    Abstract: Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: February 19, 2019
    Assignee: Tolero Pharmaceuticals, Inc.
    Inventors: Koc-Kan Ho, Yong Xu, Michael David Saunders, Xiaohui Liu, Scott Albert Pearce, Kevin Bret Wright, Jason Marc Foulks, Kenneth Mark Parnell, Steven Brian Kanner, David Lee Vollmer, Jihua Liu
  • Patent number: 10202356
    Abstract: Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 12, 2019
    Assignee: Tolero Pharmaceuticals, Inc.
    Inventors: Alexis Mollard, Steven L. Warner, Gary A. Flynn, Hariprasad Vankayalapati, David J. Bearss
  • Patent number: 10132797
    Abstract: The present disclosure is generally directed to profiling peptides, compositions, and kits, as well as methods of use thereof. The profiling peptides comprise an Mcl-1 binding domain, and optionally a cellular uptake moiety. The methods of using such profiling peptides include predicting sensitivity of a cancer, selecting a treatment, treating a cancer, producing a sensitivity profile, and the like.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: November 20, 2018
    Assignee: Tolero Pharmaceuticals, Inc.
    Inventors: David J. Bearss, Adam Siddiqui-Jain, Clifford J. Whatcott, Peter W. Peterson, Steven L. Warner, Lars Mouritsen
  • Patent number: 10047093
    Abstract: The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: August 14, 2018
    Assignee: TOLERO PHARMACEUTICALS, INC.
    Inventors: Yong Xu, Benjamin Gary Brenning, Steven G. Kultgen, Xiaohui Liu, Michael David Saunders, Koc-Kan Ho
  • Patent number: 9901574
    Abstract: The present disclosure provides diagnostic methods useful for predicting a patient's response to alvocidib and guiding a physician decision to administer alvocidib to the patient.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: February 27, 2018
    Assignee: Tolero Pharmaceuticals, Inc.
    Inventors: Steven L. Warner, David J. Bearss
  • Patent number: 9758539
    Abstract: Compounds having the following structure (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein one of R1, R2 or R3 is —P(?O)(OH)2, and the other two of R1, R2 and R3 are each H, are provided. Pharmaceutical compositions comprising the compounds, and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: September 12, 2017
    Assignee: Tolero Pharmaceuticals, Inc.
    Inventors: Adam Siddiqui-Jain, David J. Bearss
  • Patent number: 9714247
    Abstract: Kinase with inhibitory activity against kinases disposed in multiple signaling pathways and their therapeutic uses.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: July 25, 2017
    Assignees: Tolero Pharmaceuticals, Inc., Mannkind Corporation
    Inventors: Qingping Zeng, Mary Faris, Alexis Mollard, Steven L. Warner, Gary A. Flynn
  • Patent number: 9493454
    Abstract: Kinase with inhibitory activity against kinases disposed in multiple signaling pathways and their therapeutic uses.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: November 15, 2016
    Assignees: Tolero Pharmaceuticals, Inc., Mannkind Corporation
    Inventors: Qingping Zeng, Mary Faris, Alexis Mollard, Steven L. Warner, Gary A. Flynn
  • Patent number: 9416132
    Abstract: The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: August 16, 2016
    Assignee: Tolero Pharmaceuticals, Inc.
    Inventors: Yong Xu, Benjamin Gary Brenning, Steven G. Kultgen, Xiaohui Liu, Michael Saunders, Koc-Kan Ho
  • Patent number: 9394257
    Abstract: Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: July 19, 2016
    Assignee: Tolero Pharmaceuticals, Inc.
    Inventors: Koc-Kan Ho, Yong Xu, Michael David Saunders, Xiaohui Liu, Scott Albert Pearce, Kevin Bret Wright, Jason Marc Foulks, Kenneth Mark Parnell, Steven Brian Kanner, David Lee Vollmer, Jihua Liu
  • Publication number: 20140329807
    Abstract: The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.
    Type: Application
    Filed: July 20, 2012
    Publication date: November 6, 2014
    Applicant: TOLERO PHARMACEUTICALS, INC.
    Inventors: Yong Xu, Benjamin Gary Brenning, Steven G. Kultgen, Xiaohui Liu, Michael Saunders, Koc-Kan Ho